![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Abbott presents phase 3 study results for investigational use of HUMIRA
Abbott announced results from the Phase 3 ABILITY-2 investigational study of HUMIRA in patients with...
New immune therapy shows promise in kidney cancer
An antibody that helps a person's own immune system battle cancer cells shows increasing promise...
Carfilzomib demonstrates efficacy as new frontline treatment regimen for multiple myeloma
Results from a study published online in Blood, the Journal of the American Society...
Trastuzumab emtansine reduced the risk of cancer worsening or death
Roche announced that the Phase III EMILIA study of trastuzumab emtansine met its co-primary...
Boehringer Ingelheim expands development capacities with new technical centre
The research driven pharmaceutical company Boehringer Ingelheim is establishing a new 50 million-plus euro...
Bristol-Myers Squibb announces global collaboration with leading academic institutions
Bristol-Myers Squibb Company announced the formation of the International Immuno-Oncology Network (II-ON), a global...
Lundbeck’s Lu AE58054 meets primary endpoint
H. Lundbeck A/S today announced that Lu AE58054 has met its primary endpoint in...
Thioridazine, successfully kills cancer stem cells in the human
A team of scientists at McMaster University has discovered a drug, thioridazine, successfully kills...
Innovative public-private collaboration launches to tackle antibiotic research
GlaxoSmithKline and AstraZeneca welcomed the launch of a pioneering approach to antibiotic research in Europe...
Bayer’s Regorafenib submitted for EU and US marketing authorization
Bayer HealthCare has submitted a Marketing Authorization Application to the European Medicines Agency and...